Drug safety of frequently used drugs and substances for self-medication in COVID-19

Daniela Baracaldo-Santamaría, Santiago Pabón-Londoño and Luis Carlos Rojas-Rodriguez

Abstract: During the COVID-19 pandemic, the behavior of self-medication has increased. The dissemination of misleading information regarding the efficacy of certain drugs or substances for the prevention and treatment of COVID-19 has been the major contributing factor for this phenomenon. Alongside with the increase in self-medication behavior, the inherent risks to this act such as drug-drug interactions, adverse events, drug toxicity, and masking of symptoms have also increased. Self-medication in the context of COVID-19 has led to drug misuse leading in some cases to the development of fatal adverse drug reactions. It is important that during this ongoing pandemic drugs with potential clinical efficacy against COVID-19 are adequately analyzed regarding their efficacy, safety, and monitoring. The aim of this review is to describe the available evidence regarding the efficacy, safety, and monitoring of the drugs and substances that have been shown to be frequently used for self-medication in patients with COVID-19 (hydroxychloroquine, non-steroidal anti-inflammatory drugs, ivermectin, azithromycin, vitamins, aspirin, and chlorine dioxide) to adequately characterize their risks, safe use, monitoring strategies, and to reinforce the concept that these substances should not be used for self-medication and require a medical prescription.

Plain Language Summary
Drug safety of frequently used drugs and substances for self-medication in COVID-19

Dissemination of information about potential COVID-19 treatments has led individuals to self-medicate and expose themselves to risks such as drug-drug interactions, side effects, antibiotic resistance, and misdiagnosis. There is a need to review the medical literature to evaluate the safety and efficacy of the drugs and substances commonly used by the population for the treatment and prevention of SARS CoV-2 infection. In this review, we included drugs that are frequently used for self-medication and commonly advertised such as ivermectin, hydroxychloroquine, chlorine dioxide, azithromycin, and non-steroidal anti-inflammatory drugs, among others. A brief introduction of the drug and its mechanism of action, followed by a summary of the efficacy in COVID-19 and safety, will be described for each drug in order to promote their responsible use.

Keywords: aspirin, azithromycin, COVID-19, hydroxychloroquine, ivermectin, SARS CoV-2, self-medication

Received: 10 November 2021; revised manuscript accepted: 23 March 2022.
that, when practiced responsibly, can help reduce the burden on the health care system and alleviate patient symptomatology. The World Health Organization (WHO) defines responsible self-medication as the practice in which individuals treat their symptoms of illness with medicines that are approved and available without prescription, with drugs of proven safety, quality, and efficacy and for their indicated condition.1 However, self-medication in the context of the COVID-19 pandemic cannot meet these criteria because the drugs and compounds recommended for the treatment of COVID-19 to date have no proven efficacy for this disease.

At the onset of the pandemic, many drugs with *in vitro* and *in vivo* activity against SARS CoV-2 (severe acute respiratory syndrome coronavirus 2) were hypothesized to have clinical efficacy in COVID-19.2–4 As an example, hydroxychloroquine and chloroquine can have potentially life-threatening side effects if they are not carefully dosed and monitored. They were initially authorized and recommended by the FDA (Food and Drug Administration) and other regulatory agencies and guidelines5,6 for its use in hospitalized patients with COVID-19 because of encouraging evidence of *in vitro* and small uncontrolled studies.7,8 However, misleading information about their efficacy led people to self-medicate with such drugs exposing them to rare but potentially fatal harms such as ventricular arrhythmias, hepatic failure, and serious and cutaneous adverse reactions (Drug Rash with Eosinophilia and Systemic Symptoms, Steven-Johnson syndrome).9–11 Nevertheless, in light of serious cardiovascular adverse effects (QT prolongation, *torsades de pointes*, sudden death)9,12 and lack of efficacy in large randomized clinical trials such as the RECOVERY13 and Solidarity trial,14 the authorization was revoked.

Self-medication is a public health problem because it has potential risks such as adverse drug reactions (ADRs), drug–drug interactions (DDIs), antibiotic resistance, drug toxicity, incorrect choice of medication, and masking of symptoms, of which some may have lethal complications as discussed above. The prevalence of self-medication for COVID-19 prevention and management was found to be 33.9% in hospitalized adults with COVID-19 and <4–88% in the general population.15 The main reasons for self-medication were emergency illness, delays in receiving hospital services, distance to the health care facility, and proximity to the pharmacy, and the most commonly used drugs were vitamin C or multivitamins and antimalarials, obtained mainly from pharmacies.16 On the contrary, Quispe-Cañari et al.17 found in a cross-sectional multicenter study that the main drugs used for self-medication in COVID-19 were acetaminophen, ibuprofen, azithromycin, penicillin, antiretrovirals, and hydroxychloroquine for a variety of symptoms including fever, fatigue, cough, sneezing, muscle pain, nasal congestion, sore throat, headache, and breathing difficulty.

Furthermore, there is evidence suggesting that the COVID-19 pandemic has increased the reporting of ADRs associated with self-medication. For instance, Gras et al. compared the reporting of ADRs related to self-medication in a French Pharmacovigilance database in 2020 to the previous year, where they found that 3.7% of the reported ADRs were linked to self-medication compared with 1.6% in 2019. Demonstrating a higher proportion of medication errors in the COVID-19 period.18 In addition, several studies have demonstrated a high prevalence of self-medication during the pandemic; Acharya et al. found a prevalence of 50.4% of self-medication among medical students and staff of a tertiary care center. From these patients 50% purchased the drugs or substances directly from the pharmacy, and the most frequently used compounds were paracetamol, vitamin C, zinc, multivitamins, vitamin D, azithromycin, cough syrup, and ibuprofen.19 Several other questionnaire-based studies have similar results when considering the most frequently used drugs for self-medication in COVID-19; these being analgesics, anti-inflammatories, antibiotics (azithromycin), ivermectin, chloroquine, and vitamins.20–22 However, other substances such as chlorine dioxide became popular during the COVID-19 pandemic especially in Latin America.23 At the beginning of the pandemic, chlorine dioxide, a disinfectant used to treat residual waters, was advertised as a ‘miracle cure’ for COVID-19 and was even approved in some countries for the treatment and prevention of COVID-19.24 However, exposure at high doses of this substance has been linked to thyroid suppression, DNA damage, and neurotoxicity. Soriano-Moreno
et al. conducted a cross-sectional study to evaluate the prevalence and the factors associated with chlorine dioxide consumption. Of 3610 adult Peruvian participants, they found a prevalence of 8% and 16% for the prevention and treatment of COVID-19, respectively, indicating that chlorine dioxide is a substance being used for self-medication in COVID-19.25

A recent systematic review regarding self-medication practices to prevent or manage COVID-19 found that the most frequently used medications were antibiotics, chloroquine or hydroxychloroquine, vitamins or supplements, ivermectin, and ibuprofen.15 However, other drugs such as aspirin were also reported by high-quality studies.26 Based on the studies mentioned previously, the aim of this review is to describe the available evidence regarding the efficacy, safety, and monitoring of the drugs and substances that have been shown to be frequently used for self-medication in patients with COVID-19 [hydroxychloroquine, non-steroidal anti-inflammatory drugs (NSAIDs), ivermectin, azithromycin, vitamins, chlorine dioxide, aspirin] to adequately characterize their risks, safe use, monitoring strategies, and to reinforce the concept that these substances should not be used for self-medication and require a medical prescription.

Drug used for self-medication in COVID-19

Hydroxychloroquine

Hydroxychloroquine is a chemically synthesized disease-modifying drug that belongs to the 4-aminoquinolines drug class and is currently used for the treatment of several autoimmune diseases;27 most importantly systemic lupus erythematosus (SLE) where it has shown to be more effective.28 It has been linked with antimalarial, anti-inflammatory, anti-infectious, and immunomodulatory effects. The majority of hydroxychloroquine mechanisms of actions are attributed to its properties as a weak base and as a highly lipophilic compound, which allows it to enter lysosomes, endosomes, and autophagosomes increasing their pH and thereby interfering with vesicular enzyme function (conversion of heme to hemozoin in the malaria parasite, interference with antigen processing and presentation, inhibiting virus-cell membrane fusion).29 The increased pH caused by hydroxychloroquine in the endosome containing MHCII (major histocompatibility complex II) prevents the clipping of the invariant chain and thus the formation of the MHCII/peptide complex (usually only with low-affinity antigens such as self-antigens)27 ultimately leading to interference of cytokine release, B cell activation, and induction of apoptosis of autoreactive T-cells. Recently, inhibition of toll-like receptor signaling has also been attributed to hydroxychloroquine. Given its anti-inflammatory and potential antiviral properties, it was a rational compound to be evaluated against SARS CoV-2. In vitro studies showed that chloroquine and hydroxychloroquine could inhibit the entry of SARS CoV-2 into the cell.30

Efficacy in COVID-19. Due to in vitro evidence of hydroxychloroquine and chloroquine antiviral activity against SARS CoV-2,7,8 several clinical trials on their use in COVID-19 have emerged, albeit with contradictory results.31–35 A recent meta-analysis reviewed only blinded, placebo-controlled RCTs (randomized controlled trials) to evaluate the efficacy and safety of hydroxychloroquine as prophylaxis and treatment for COVID-19.36 Hydroxychloroquine as pre- and post-exposure prophylaxis showed no decrease in the risk of SARS CoV-2 infection, as treatment of non-hospitalized patients it showed no decrease in the risk of hospitalization or death, and individually the results showed no clinical benefit. Regarding hydroxychloroquine for the treatment of hospitalized patients with COVID-19, they found no difference in the duration of hospital stay, no decreased risk for mechanical ventilation between patients treated with hydroxychloroquine versus placebo.36 Furthermore, a meta-analysis of RCTs evaluating the effect of azithromycin and hydroxychloroquine in the treatment of hospitalized patients with COVID-19 found that azithromycin with or without hydroxychloroquine had no effect on mortality or on the requirement for mechanical ventilation.37

Safety and monitoring. Hydroxychloroquine is generally safe; however, it is a substrate for CYP2 C8, CYP3A4/5, and CYP2D6;38 therefore, it is susceptible to many pharmacokineti interactions of which some have clinically significant DDIs. Gastrointestinal adverse reactions such as nausea, vomiting, abdominal pain, and diarrhea are the main ADRs associated with hydroxychloroquine; therefore, it is recommended to be taken with meals. Rare cases of elevated liver function tests (LFT) and fulminant liver failure have been
Cardiotoxicity occurs after chronic exposure to hydroxychloroquine as a result of interference with lysosomal function that leads to the accumulation of glycogen and phospholipids. However, acute conduction abnormalities have also been described, as hydroxychloroquine blocks the \( I_{kr} \) (rapid component of the delayed rectifier potassium current) on the cardiac action potential through inhibition of the Kv 11.1 potassium channel leading to *torsades de pointes*.40 This was a major problem at the beginning of the pandemic because many drugs with QT interval prolongation potential were used concomitantly.41–43

On the contrary, hydroxychloroquine-induced lysosomal dysfunction also leads to the accumulation of lipofuscin, which is toxic to the photoreceptors and the retinal epithelial cells, seen in hydroxychloroquine-induced ocular toxicity.27 Extrapolated information of hydroxychloroquine management in SLE is mentioned regarding monitoring during chronic treatment. It is important to consider that a daily dose of hydroxychloroquine of >5 mg/kg (real weight); chronic kidney disease stage 3, 4, or 5; cumulative dose of >600–1000; and adjuvant tamoxifen therapy are risk factors for ocular toxicity and must be taken into account.44 A basic ophthalmological check-up should be obtained within the first 6 months of treatment. In case of chronic kidney disease with glomerular filtration rate <30 ml/min, dose must be adjusted to a maximum of 3 mg/kg. Regarding myopathies or cardiomyopathies, creatinine kinase and lactate dehydrogenase should be measured before starting the treatment and every 3–6 months.44 Muscle strength and tendon reflexes surveillance should also be monitored. Monitoring for acute treatment with hydroxychloroquine should involve assessing the risk factors for QT interval prolongation such as electrolyte abnormalities, renal failure, structural heart disease, and concomitant use of other drugs with known risk of QT prolongation.40

**Ivermectin**

Ivermectin is a drug used for its antiparasitic activities in daily clinical practice. During the pandemic, it showed inhibitory properties on SARS CoV-2 replication as well as with other viruses.45 The proposed mechanism of action is the binding and destabilizing of the importin (IMP) \( \alpha/\beta1 \)-heterodimer, thereby preventing IMP\(\alpha/\beta1 \) from binding to the viral protein and preventing it from entering the nucleus.2 This could increase viral clearance and thus decrease the likelihood of developing the infectious process.40 It has been one of the most mentioned drugs during the pandemic due to its antiviral potential, with multiple results in elaborated studies that tend to be with small populations and in non-standardized schemes for the management of such condition.17

**Efficacy in COVID-19.** Cruciani *et al.* published in their meta-analysis that there were no differences in mortality between ivermectin treatment arm and the control groups (low level of certainty). In patients with severe baseline diseases (3 reports, 304 patients), the use of ivermectin significantly decreased mortality compared with controls. Regarding disease progression [to severe pneumonia, admission to intensive care unit (ICU), and mechanical ventilation], the results were the same. The evidence is limited and approximately 36% of the studies had a high probability of performance bias.48 A systematic review of the literature reported that ivermectin may have an impact on decreasing mortality and viral clearance. However, the therapeutic regimens varied in different studies and with important limitations from the methodological design.49

A Cochrane review assessed the efficacy and safety of ivermectin compared with standard of care, placebo, or any other proven intervention for people with COVID-19 receiving inpatient or outpatient treatment and for the prevention of infection with SARS CoV-2. The authors concluded that they were uncertain about the efficacy and safety of ivermectin used to treat or prevent COVID-19 based on the available evidence.50 Some experimental studies in murine models record that eventually the mixture between remdesivir and ivermectin could have a synergistic effect in the management of patients with SARS CoV-2 infection.51 Still, we hope to see some results from a meta-analysis studying the impact of ivermectin in the population.52,53

**Safety and monitoring.** Pedrozo *et al.* analyzed in a small group, the characteristics of self-medication in healthcare workers diagnosed with COVID-19. When analyzing the group that took ivermectin, they found that there were no statistically significant differences in clinical severity;
however, abdominal pain, diarrhea, and taste alterations were more frequent in those who received multiple doses of this drug.54

In the study conducted by Popp et al.,50 the record on the presence of adverse reactions at 10, 14, and 28 days was not conclusive. Mohan et al.,55 in their study, recorded a frequency of abdominal pain of 11.2%; they did not detect serious adverse events with doses of 12 and 24 mg of ivermectin. Cruciani et al.,48 in his meta-analysis, describe an estimated frequency between 1% and 2%.

When using ivermectin, it is recommended to monitor skin reactions, as well as vertigo, ataxia, confusion, tachycardia, orthostatic hypotension, and increased transaminases.56

The FDA and other institutions in charge of drug surveillance currently recommend not using the drug for this indication until conclusive studies are available to support this recommendation.57

**Azithromycin**

Macrolides are bacteriostatic agents, derived from Streptomyces erythreus. Azithromycin is a semi-synthetic derivative of erythromycin, the first macrolide. It acts through reversible binding to the 50s subunit of the bacterial ribosome interfering with the translocation of the tRNA molecules on the ribosome from the acceptor site to the peptidyl site, resulting in impaired protein synthesis.

**Efficacy in COVID-19.** Its antibacterial role supported its use in COVID-19 infection; however, studies have failed to show effectiveness, at least in monotherapy.58-60 Alveolar damage due to SARS CoV-2 infection results in higher risk of bacterial co-infection; in such cases, there are international guidelines (The National Institute for Health and Care Excellence, American Thoracic Society and Infectious Diseases Society of America) that recommend the use of antibiotics considering the microbiological and clinical evidence to guide the appropriate therapy.61 The usage of antibiotics such as azithromycin is not advised unless there is evidence of bacterial pneumonia.62

Aside from its antibacterial activity, azithromycin has an immunomodulatory effect. *In vitro* studies have shown how azithromycin regulates many inflammatory pathways including ERK ½ (extracellular signal-regulated kinase) and NF-kB (nuclear factor kappa light chain enhancer of activated B cells) signaling proteins involved in cytokine production, one of the identified factors attributed to COVID-19 mortality. To date, there is no evidence of antiviral activity against SARS CoV-2 unlike other viruses like Ebola or Zika. Since the beginning of the pandemic, some studies reported a significant decrease in viral load with a short course of treatment (3–6 days) with azithromycin 500 mg per day on the first day and 250 mg per day plus hydroxychloroquine.63,64 However, they had randomization issues, short samples, along with methodological pitfalls that could bias the results. A systematic review even found an increase of 7% in mortality in patients receiving both drugs in non-randomized studies.65 Despite all the biological effects associated with azithromycin, studies had failed to show effectiveness alone or together with antimalarials in reducing the need for oxygen therapy, ICU management, length of stay, or mortality associated with COVID-19.66,67

**Safety and monitoring.** One of the main concerns is the risk of QTc interval prolongation defined in most trials as significative when >500 ms or an increase of more than 60 ms from the baseline. Since the onset of the pandemic, reports of cardiovascular adverse effects including QTc prolongation and ventricular arrhythmias have increased, even in indications other than COVID-19 leading to a revoke of FDA emergency authorization for the use of drugs such as hydroxychloroquine and azithromycin in COVID-19 treatment.68 Studies show that there is a significant increased risk for QTc prolongation in combination with hydroxychloroquine within the first 4 days of treatment, in comparison with monotherapy, with substantial decrease in QTc after stopping the medication.42,67 Furthermore, the risk of fatal cardiac outcomes (TdP, ventricular tachycardia, ventricular fibrillation, or cardiac arrest) is associated with azithromycin plus hydroxychloroquine with up to 12.27% increase in average risk of severe arrhythmia; however, the population with coronary artery disease and congestive heart failure are at higher risk.67 A retrospective study found a TdP risk of 0.4% in 251 patients with COVID-19, much higher than other well-known QTc prolonging drugs that have a risk of 0.1% such as
sotalol.\(^\text{42}\) There is heterogeneity in the baseline characteristics of the selected patients and not all risk factors that predispose to a QTc prolongation were taken into account in the analysis of all studies (sex, chronic diseases, age, electrolytic alterations, genetic factor), in that way, the risk in certain populations is still unknown, for example, younger patients may be at a lower risk, due to low prevalence of structural heart disease compared with older populations. On the contrary, azithromycin alone has not shown any considerable risk for these complications, remarking the importance of drug interactions in measuring the overall risk of QTc prolongation.\(^\text{69–71}\) In light of this evidence, it is advisable to maintain close electrocardiographic monitoring, when azithromycin is used in combination with hydroxychloroquine or other QT prolonging drugs. It should be taken into consideration that it is more difficult to assess QTc prolongation in cases where prolongation of QRS is also an issue; as in the case of antimalarials, in these cases certain groups have opted to measure the JTc interval measuring from the J point at the beginning of the ST segment to the end of the T wave, correlating a measure of 410 ms with 500 ms of the QT interval.\(^\text{42}\)

Other adverse effects related to azithromycin therapy include gastrointestinal distress, hepatotoxicity, and hypersensibility reactions, but none of these have been relevant in COVID-19 treatment.\(^\text{67}\)

**Non-steroidal anti-inflammatory drugs**

NSAIDs are widely used around the world for musculoskeletal inflammatory conditions as well as for the management of nociceptive pain and sometimes as an antipyretic. The mechanism of action is through inhibition of cyclooxygenase (COX) 1 and 2, also known as prostaglandin endoperoxide synthetase, its selectivity on the enzyme isoform is given mainly by its chemical structure. As a result, the production of prostaglandins and thromboxane A2 from the synthesis of arachidonic acid is decreased.\(^\text{72}\)

Prostaglandins synthesis has been related to the proinflammatory activity of SARS CoV-2, as well as its entry into the host and its respective replication. Several investigators have reported the interaction of prostaglandin receptors, such as EPR4 (prostaglandin E2 receptor 4), associated with cell surface binding to immunoglobulins. At the same time, SARS CoV-2 infection has shown a significant increase in the synthesis and expression of COX-1 and COX-2 as well as up-regulation of PGE2 production in mononuclear cells. On the contrary, an effect on the innate immune response has been observed.\(^\text{72}\)

**Efficacy in COVID-19.** The debate on whether NSAIDs (especially ibuprofen) increased susceptibility to acquire SARS CoV-2 infection was discussed since the onset of the pandemic. Some data revealed that there was up-regulation of ACE2 (angiotensin-converting enzyme) receptors as well as masking of symptoms such as fever. However, multiple regulatory bodies did not make recommendations in this regard due to lack of conclusive evidence.\(^\text{73}\)

Lund *et al.* conducted a population-based cohort study analyzing the impact of NSAIDs use in SARS CoV-2-positive patients. In matched analyses, treatment with NSAIDs was not associated with mortality, risk of ICU hospitalization, mechanical ventilation, or renal replacement therapy.\(^\text{74}\) Some of the limitations of the study could be related to the use of NSAIDs to treat early symptoms of SARS CoV-2 disease, as well as the lack of knowledge about the prescribed therapeutic regimen and adherence to it.\(^\text{74}\) Several meta-analyses have shown that using NSAIDs, including ibuprofen, does not increase the risk of serious complications such as severe acute respiratory distress syndrome (ARDS), hospitalization, ICU admission, and death, in patients both confirmed and suspected of SARS CoV-2 infection.\(^\text{75,76}\)

**Safety and monitoring.** In a retrospective observational cohort study, the use of NSAIDs has been associated with an increased risk for the development of acute kidney injury in patients with COVID-19.\(^\text{75}\) However, it is important to analyze that several of them also received multiple antibiotic drugs such as vancomycin, piperacillin/tazobactam, and aminoglycosides with a significant risk of associated nephrotoxicity.\(^\text{77}\)

The risk of gastrointestinal injury is associated with the mechanism of action of NSAIDs, and in general, higher doses are associated with this outcome.\(^\text{78}\) Even with selective COX-2 inhibitors, gastrointestinal injury has also been described.
For treating COVID-19, this might not be a major drawback since the expected duration of treatment will not exceed a few days to weeks. However, patients with significant cardiovascular comorbidities (e.g. obesity, uncontrolled diabetes, coronary artery disease, or ischemic stroke) might not be ideal candidates for using this agent.79

For the prescription of NSAIDs in general, recommendations extrapolated from conventional scenarios are made. Monitor the patient’s dose and comorbidities (e.g. obesity, uncontrolled diabetes mellitus, cardiovascular disease), as well as serum creatinine, urea nitrogen, blood count, and transaminases (occasionally elevated in patients with SARS CoV-2 infection). It is also suggested not to maintain prolonged periods.78

**Acetylsalicylic acid**

As with NSAIDs, the use of acetylsalicylic acid (ASA) has been widely debated, in principle because of the risk of coagulopathy due to endothelial dysfunction and microvascular thrombosis that may occur in people with SARS CoV-2 infection.80 ASA is associated with a reduction in atherosclerotic cardiovascular disease (ASCVD) when used for primary prevention; however, it is unlikely to be clinically significant given the increase in bleeding. More importantly, the effect of aspirin’s treatment effect does not increase as ASCVD risk increases, as many hypothesize.81,82

**Efficacy in COVID-19.** There are multiple studies with variable results to confirm whether the use of ASA is associated with an impact on morbidity and mortality in patients with COVID-19;83 however, population size, patient admission characteristics during health care, and the use of other medications may eventually be limiting to the studies.72

Kow and Hassan published a meta-analysis in which they reported reduced risk of severe COVID-19 with aspirin use relative to no treatment (pooled odds ratio = 0.50; 95% confidence interval = 0.32–0.77).84 Likewise, in the meta-analysis by Ritika and Anoop, the odds ratio was found to be 0.70 [0.63, 0.77] indicating a lower probability of death in COVID-19 patients in the aspirin group compared with non-aspirin group. However, no effect 0.00 [−0.04, 0.04] was observed after the exclusion of outliers.85

On the contrary, Sahai et al.86 performed a descriptive analysis in which they reported that the use of low doses of ASA had no significant impact on mortality versus those not taking this drug (13.3%–15.3%, $p = 0.53$); however, using the composite thrombotic endpoint of MI (myocardial infarction), VTE (venous thromboembolisms), and thrombotic stroke, aspirin was associated with more thrombotic events (9.3% aspirin versus 2.8% non-aspirin; $p = 0.005$).74

Although multiple studies consider that there is no significant impact on mortality, the evidence remains variable87 and it is important to continue evaluating the impact of this type of drug on COVID-19 outcomes.

**Safety and monitoring.** Although there are not many studies that have analyzed the safety of ASA in patients with SARS CoV-2, it is important to remember that this condition usually presents not only with thrombotic events but also with bleeding and thrombocytopenia, so the risk of bleeding should be taken into account. Likewise, in patients who present with cardiovascular thrombotic events and require both anticoagulation and antiplatelet therapy, ASA should be used with caution.74,76

**Vitamins (ascorbic acid)**

Vitamin C has been proposed for the treatment of respiratory infections since it was isolated in the 1930s88 and, for this reason, it has also been one of the most commonly used drugs during the pandemic. Recent studies suggest that ascorbic acid may attenuate pathological responses in the septic microvasculature. Some studies have shown that ascorbic acid infusion improved capillary blood flow and micro and arteriolar responsiveness to vasoconstrictors in septic animals.89,90

It is a hydrophilic substance that limits its passage through simple diffusion. Absorption, distribution, and elimination are handled by the sodium-dependent vitamin C transporter (SVCT) family of proteins that cotransports sodium ions and ascorbate (ASC).91
Because of its antioxidant, immunomodulatory, and secondary anti-inflammatory mechanism, it could become a pharmacological strategy to treat patients with SARS CoV-2 infection.\textsuperscript{45}

**Efficacy in COVID-19.** There are few clinical trials that have studied the impact of ascorbic acid on mortality in patients with SARS CoV-2 infection. And those that have been performed have multiple limitations as well as small study populations.\textsuperscript{92,93}

Tomasa-Irriguible and Bielsa-Berrocal have recorded that the most critical patients admitted to the ICU had low or undetectable serum vitamin C levels. However, due to their limitations, they suggest further studies to confirm this finding in this condition.\textsuperscript{94} Some studies conducted in China and Finland have suggested that the use of high doses of vitamin C could reduce the duration of respiratory symptoms such as cough, fatigue, and shortness of breath, as well as increase the PaO\textsubscript{2}/FiO\textsubscript{2} ratio.\textsuperscript{95,96}

Thomas et al.\textsuperscript{97} conducted an open-label randomized factorial trial using vitamin C; however, the study was terminated for lack of benefits after the interim analysis.

Now, there are still protocols under development analyzing the outcomes with ascorbic acid and vitamin D supplementation.\textsuperscript{98,99}

**Safety and monitoring.** Among the adverse effects recorded with high doses of ascorbic acid are acute tubular injury and oxalate nephropathy, so it would be pertinent to monitor in patients with associated renal disease or with multiple risk factors associated with renal injury.\textsuperscript{95}

Likewise, in patients with a history of glucose-6-phosphate dehydrogenase deficiency, a risk of hemolysis has been reported.\textsuperscript{100}

**Chlorine dioxide and chlorine derivatives**

Chlorine dioxide (ClO\textsubscript{2}) and other chlorine derivatives are used as disinfecting agents in many scenarios due to their strong oxidant properties. ClO\textsubscript{2} usually derives from sodium chlorite mixed with a solution of water and other acids.\textsuperscript{101} The inactivation and denaturing of many proteins results in damage of organic compounds, including virus inactivation. ClO\textsubscript{2} has been demonstrated to inactivate bacterial viruses through interaction with viral capsid proteins without significant damage to RNA material. Since then, it has been hypothesized that ClO\textsubscript{2} interacts with amino acid residues, mainly cysteine, tyrosine, tryptophan, histidine, hydroxyproline, and proline in a slower rate.\textsuperscript{102} For example, antimicrobial activity against influenza virus was related with denaturing of a hemagglutinin through a tryptophan residue, interfering with its receptor-binding capacity.\textsuperscript{103} SARS CoV-2 contains a similar protein with 54 tyrosine, 12 tryptophan, and 40 cysteine residues.\textsuperscript{104}

To be effective, ClO\textsubscript{2} must be used in aqueous solution, so using moisturized gas can also inactivate environmental particles of viruses. There are disinfection methods that used sprayed ClO\textsubscript{2} solutions to achieve faster dispersion without reaching limit values, 0.1 ppm TWA and 0.3 ppm STEL.\textsuperscript{105}

**Evidence in COVID-19.** The presence of SARS CoV-2 in the mouth and upper and lower respiratory tract leads to the biological plausibility that disinfection of the nasal and oral cavity through direct application of ClO\textsubscript{2} could decrease the viral load. Its disinfecting properties lead to widespread advertisements of ClO\textsubscript{2} containing products to prevent and treat COVID-19 when administered by oral or parenteral route. A Cochrane review of antimicrobial mouthwashes and nasal sprays administered to patients with suspected or confirmed COVID-19 infection found a lack of clinical evidence for the efficacy of these approaches, lacking serious academic research regarding these products, with no information on changes in COVID-19 viral load in patients, the incidence of COVID-19-positive test or infection, or adverse effects, such as anosmia changes in the local microbiome in the oral cavity, nasal cavity, or pharynx.\textsuperscript{106}

Human alveoli can be affected by the oxidizing properties of ClO\textsubscript{2}; in sufficient amount ClO\textsubscript{2} can decrease glutathione and other antioxidants by interacting directly with epithelial cells, leading to lung injury when environmental permitted limit values are surpassed. The FDA has received reports of ventricular arrythmia, methemoglobinemia, hemolytic anemia associated with
liver dysfunction, and diarrhea when oral products are ingested.105

Safety and monitoring. To date, The Pan American Health Organization (PAHO) does not recommend the use of chlorine dioxide or sodium chlorite by oral or parenteral route in patients with suspected or diagnosed with COVID-19.107 Currently, there is no ongoing relevant study, likely due to no biological plausibility or preliminary clinical evidence to support its effectiveness in prevention or treatment and the risk of potential severe adverse effects.

Conclusion
In conclusion, self-medication is a natural behavior in response to a complex situation such as the COVID-19 pandemic. However, self-medication has associated risk factors to develop ADRs and DDIs and therefore healthcare professionals must recognize and approach this practice to assure the correct use of drugs. Most of the drugs used in self-medication for COVID-19 have poor evidence, and the available studies have important limitations. Self-medication was driven by the massive dissemination of misleading information at the onset of the pandemic, accompanied by the emergency authorization of regulatory agencies. The media should take responsibility for the information they give about therapeutics and they should support responsible self-medication and the rational use of medicines. There is a need to educate the general population about the advertised drugs and substances for the prevention and treatment of COVID-19 to avoid the risks of self-medication.

Author contributions
Daniela Baracaldo–Santamaría: Conceptualization; Investigation; Methodology; Writing – original draft; Writing – review & editing.

Santiago Pabón-Londoño: Conceptualization; Investigation; Writing – original draft.

Luis Carlos Rojas-Rodriguez: Conceptualization; Investigation; Methodology; Project administration; Supervision; Validation; Visualization; Writing – original draft; Writing – review & editing.

Conflict of interest statement
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This project was supported by Universidad del Rosario.

ORCID iD
Luis Carlos Rojas-Rodriguez https://orcid.org/0000-0002-9989-6980

References
1. World Health Organization. The role of the pharmacist in self-care and self-medication. Geneva: World Health Organization, 1998.
2. Caly L, Druce JD, Catton MG, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 2020; 178: 104787.
3. Kang CK, Seong M-W, Choi S-J, et al. In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses. Korean J Intern Med 2020; 35: 728.
4. Fantini J, Di Scala C, Chahinian H, et al. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int J Antimicrob Agents 2020; 55: 105960.
5. Asociación Colombiana de infectología Asociación Colombiana de Infectología–ACIN Bogotá 24 de Mayo de 2020.
6. Ministerio de salud y protección social Se Retira Recomendación de Cloroquina, Hidroxiclороquina y Lopinavir/Ritonavir Para Tratar Covid-19. https://www.minsalud.gov.co/Paginas/Se-retira-recomendacion-de-cloroquina-hidroxiclороquina-y-lopinavir-ritonavir-para-tratar-covid-19.aspx (accessed 6 November 2021).
7. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-NCoV) in vitro. Cell Res 2020; 30: 269–271.
8. Keyaerts E, Vigen L, Maes P, et al. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun 2004; 323: 264–268.
9. Jankelson L, Karam G, Becker M, et al. QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19:
a systematic review. *Heart Rhythm* 2020; 17: 1472–1479.

10. Mallhi TH, Khan YH, Alotaibi NH, *et al.* Drug repurposing for COVID-19: a potential threat of self-medication and controlling measures. *Postgrad Med J* 2021; 97: 742–743.

11. Ferner RE and Aronson JK. Chloroquine and Hydroxychloroquine in Covid-19. *BMJ* 2020; 369: m1432.

12. Nguyen L, Dolladille C, Drici M, *et al.* Cardiovascular toxicities associated with hydroxychloroquine and azithromycin: an analysis of the World Health Organization pharmacovigilance database. *Circulation* 2020; 142: 303–305.

13. The RECOVERY Collaborative Group. Effect of hydroxychloroquine in hospitalized patients with Covid-19. *N Engl J Med* 2020; 383: 2030–2040.

14. WHO Solidarity Trial Consortium. Repurposed antiviral drugs for Covid-19 – Interim WHO solidarity trial results. *N Engl J Med* 2020; 384: 497–511.

15. Quincho-Lopez A, Benites-Ibarra CA, Hilario-Gomez MM, *et al.* Self-medication practices to prevent or manage COVID-19: a systematic review. *PLoS ONE* 2020; 16: e0259317.

16. Wegbom AI, Edet CK, Raimi O, *et al.* Self-medication practices and associated factors in the prevention and/or treatment of COVID-19 virus: a population-based survey in Nigeria. *Front Public Health* 2021; 9: 606801.

17. Quispe-Cañari JF, Fidel-Rosales E, Manrique D, *et al.* Self-medication practices during the COVID-19 pandemic among the adult population in Peru: a cross-sectional survey. *Saudy Pharm J* 2021; 29: 1–11.

18. Gras M, Gras-Champel V, Moragny J, *et al.* Impact of the COVID-19 outbreak on the reporting of adverse drug reactions associated with self-medication. *Ann Pharm Fr* 2021; 79: 522–529.

19. Acharya A, Vaidya Shrestha M and Karki D. Self-medication among medical students and staffs of a Tertiary Care Centre during COVID-19 pandemic: a descriptive cross-sectional study. *J Nepal Med Assoc* 2022; 60: 59–62.

20. Navarrete-Mejia PJ, Velasco-Guerrero JC and Loro-Chero L. Automedicación En Época de Pandemia: Covid-19. *Rev Cuerpo Méd HNAAA* 2021; 13: 350–355.

21. Okoye OC, Adejumo OA, Opadeyi AO, *et al.* Self medication practices and its determinants in health care professionals during the coronavirus disease-2019 pandemic: cross-sectional study. *Int J Clin Pharm.* Epub ahead of print 12 January 2022. DOI: 10.1007/S11096-021-01374-4.

22. Saleem R, Butt M, Ahmad A, *et al.* Practices and attitude of self-medication during COVID-19 pandemic in university students with interventional role of pharmacist: a regional analysis-web of science core collection. *Latin Am J Pharm* 2021; 40: 1946–1953.

23. Mostajo-Radji MA. Pseudoscience in the times of crisis: how and why chlorine dioxide consumption became popular in Latin America during the COVID-19 pandemic. *Front Politi Sci* 2021; 3: 621370.

24. How Bolivia embraced toxic bleach as a COVID-19 miracle cure. https://www.businessinsider.com/bolivia-bleach-coronavirus-embraced-misinformation-2020-9 (accessed 1 March 2022).

25. Soriano-Moreno DR, Fernandez-Guzman D, Ccami-Bernal F, *et al.* Factors associated with the consumption of chlorine dioxide to prevent and treat COVID-19 in the Peruvian population: a cross-sectional study. *BMC Public Health* 2021; 21: 2109.

26. Miñan-Tapia A, Conde-Escobar A and Calderon-Arce D. View of associated factors to self-medication with drugs related to COVID-19 in health science students from a Peruvian City. *SciELO Preprints* 2020, https://preprints.scielo.org/index.php/scielo/preprint/view/1225

27. Schrezenmeier E and Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. *Nat Rev Rheumatol* 2020; 16: 155–166.

28. Monzavi SM, Alirezaei A, Shariati-Sarabi Z, *et al.* Efficacy analysis of hydroxychloroquine therapy in systemic lupus erythematosus: a study on disease activity and immunological biomarkers. *Inflammopharmacology* 2018; 26: 1175–1182.

29. Bansal P, Goyal A, Cusick AIV, *et al.* Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019. *Ann Med* 2020; 53: 117–134.

30. Liu J, Cao R, Xu M, *et al.* Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. *Cell Discov* 2020; 6: 16–14.

31. di Castelnuovo A, Costanzo S, Cassone A, *et al.* Low dose hydroxychloroquine is associated with lower mortality in COVID-19: a meta-analysis of
26 studies and 44,521 patients. *MedRxiv* 2020. DOI: 10.1101/2020.11.01.20223958.

32. Million M, Gautret P, Colson P, *et al.* Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world. *New Microbes New Infect* 2020; 38: 100709.

33. Eze P, Mezue KN, Nduka CU, *et al.* Efficacy and safety of chloroquine and hydroxychloroquine for treatment of COVID-19 patients—a systematic review and meta-analysis of randomized controlled trials. *Am J Cardiovasc Dis* 2021; 11: 93–107.

34. Bartoszko JJ, Siemieniuk RAC, Kum E, *et al.* Prophylaxis against Covid-19: living systematic review and network meta-analysis. *BMJ* 2021; 373: n949.

35. Axfors C, Schmitt AM, Janiaud P, *et al.* Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials. *Medrxiv* 2020. DOI: 10.1101/2020.09.16.20194571.

36. Martins-Filho PR, Ferreira LC, Heimfarth L, *et al.* Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19: a systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials. *Lancet Reg Health Am* 2021; 2: 100062.

37. Chi G, Memar Montazerin S, Lee JJ, *et al.* Effect of azithromycin and hydroxychloroquine in patients hospitalized with COVID-19: network meta-analysis of randomized controlled trials. *J Med Virol* 2021; 93: 6737–6749.

38. Biswas M and Roy DN. Potential clinically significant drug-drug interactions of hydroxychloroquine used in the treatment of COVID-19. *Int J Clin Pract* 2021; 75: e14710.

39. Abdel Galil SM. Hydroxychloroquine-induced toxic hepatitis in a patient with systemic lupus erythematosus: a case report. *Lupus* 2015; 24: 638–640.

40. Baracaldo-Santamaría D, Llinás-Caballero K, Corso-Ramirez JM, *et al.* Genetic and molecular aspects of drug-induced QT interval prolongation. *Int J Mol Sci* 2021; 22: 8090.

41. Hodge C, Marra F, Marzolini C, *et al.* Drug interactions: a review of the unseen danger of experimental COVID-19 therapies. *J Antimicrob Chemother* 2020; 75: 3417–3424.

42. Chorin E, Wadhwani L, Magnani S, *et al.* QT interval prolongation and Torsade de Pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. *Heart Rhythm* 2020; 17: 1425–1433.

43. Lazzerini PE, Boutjdir M and Capecci PL. COVID-19, arrhythmic risk, and inflammation. *Circulation* 2020; 142: 7–9.

44. Fiehn C, Ness T, Weseloh C, *et al.* Safety management in treatment with antimalarials in rheumatology. Interdisciplinary recommendations on the basis of a systematic literature review. *Z Rheumatol* 2020; 80: 1–9.

45. Chowdhury A, Sajjd M, Jahan N, *et al.* A secondary approach with conventional medicines and supplements to recuperate current COVID-19 status. *Biomed Pharmacother* 2021; 142: 111956.

46. Bryant A, Laurie T, Dowswell T, *et al.* Ivermectin for prevention and treatment of COVID-19 infection: a systematic review, meta-analysis, and trial sequential analysis to inform clinical guidelines. *Am J Ther* 2021; 28: e434–e460.

47. Reardon S. Flawed ivermectin preprint highlights challenges of COVID drug studies. *Nature* 2021; 596: 173–174.

48. Cruciani M, Pati I, Masiello F, *et al.* Ivermectin for prophylaxis and treatment of COVID-19: a systematic review and meta-analysis. *Diagnoses* 2021; 11: 1645.

49. Chaudhry MW, Zubair SM, Zubairi ABS, *et al.* Role of ivermectin in patients hospitalized with COVID-19: a systematic review of literature. *Adv Respir Med* 2021; 89: 413–418.

50. Popp M, Stegemann M, Metzendorf MI, *et al.* Ivermectin for preventing and treating COVID-19. *Cochrane Database Syst Rev* 2021; 7: CD015017.

51. Tan YL, Tan KSW, Chu JJH, *et al.* Combination treatment with remdesivir and ivermectin exerts highly synergistic and potent antiviral activity against murine coronavirus infection. *Front Cell Infect Microbiol* 2021; 11: 700502.

52. Ashraf S, Ashraf S, Farooq I, *et al.* Anti-COVID property of subcutaneous ivermectin in synergy with zinc among midlife moderately symptomatic patients: a structured summary of a study protocol for a randomised controlled trial. *Trials* 2021; 22: 591.

53. de Lima Machado ML, Souza ATB, Linhares PVA, *et al.* Effectiveness and safety of ivermectin in the treatment of COVID-19: protocol for a systematic review and meta-analysis. *BMJ Open* 2021; 11: e050532.
54. Pedroso C, Vaz S, Netto EM, et al. Self-prescribed ivermectin use is associated with a lower rate of seroconversion in health care workers diagnosed with COVID, in a dose-dependent response. Braz J Infect Dis 2021; 25: 101603.

55. Mohan A, Tiwari P, Suri TM, et al. Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): a single-centre randomized, placebo-controlled trial. Infect Chemother 2021; 27: 1743–1749.

56. Chandler RE. Serious neurological adverse events after ivermectin – do they occur beyond the indication of onchocerciasis? Am J Trop Med Hyg 2018; 98: 382–388.

57. Kory P, Meduri GU, Varon J, et al. Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19. Am J Ther 2021; 28: e299–e318.

58. Pani A, Lauriola M, Romandini A, et al. Macrolides and viral infections: focus on azithromycin in COVID-19 pathology. Int J Antimicrob Agents 2020; 56: 106053.

59. Damle B, Vourvahis M, Wang E, et al. Clinical pharmacology perspectives on the antiviral activity of azithromycin and use in COVID-19. Clin Pharmacol Ther 2020; 108: 201–211.

60. Echeverría-Esnal D, Martin-Ontiyuelo C, Navarrete-Rouco ME, et al. Azithromycin in the treatment of COVID-19: a review. Expert Rev Anti Infect Ther 2020; 19: 147–163.

61. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019; 200: E45–E67.

62. Sultana J, Cutroneo PM, Crisafulli S, et al. Azithromycin in COVID-19 patients: pharmacological mechanism, clinical evidence and prescribing guidelines. Drug Saf 2020; 43: 691–698.

63. Jean SS, Lee PI and Hsueh PR. Treatment options for COVID-19: the reality and challenges. Microbiol Immunol Infect 2020; 53: 436–443.

64. Gautret P, Lagier J, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2021; 56: 105949.

65. Fiolet T, Guihur A, Rebeaud ME, et al. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. Clin Microbiol Infect 2021; 27: 19–27.

66. Arshad S, Kilgore P, Chaudhry ZS, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Infect Dis 2020; 97: 396–403.

67. Kim MS, An MH, Kim WJ, et al. Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: a systematic review and network meta-analysis. PLoS Med 2020; 17: e1003501.

68. Oshikoya KA, Wharton GT, Avant D, et al. Serious adverse events associated with off-label use of azithromycin or fentanyl in children in intensive care units: a retrospective chart review. Paediatr Drugs 2019; 21: 47–58.

69. Ramireddy A, Chugh H, Reinier K, et al. Experience with hydroxychloroquine and azithromycin in the coronavirus disease 2019 pandemic: implications for Qt interval monitoring. J Am Heart Assoc 2020; 9: 17144.

70. Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA 2020; 323: 2493–2502.

71. Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N Engl J Med 2020; 383: 2041–2052.

72. Ricciotti E, Laudanski K and FitzGerald GA. Nonsteroidal anti-inflammatory drugs and glucocorticoids in COVID-19. Adv Biol Regul 2021; 81: 100818.

73. Poutoglou F, Saitis A and Kouvelas D. Ibuprofen and COVID-19 disease: separating the myths from facts. Expert Rev Respir Med 2021; 15: 979–983.

74. Lund LC, Kristensen KB, Reilev M, et al. Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs and glucocorticoids in COVID-19. Inflammopharmacology 2021; 29: 641–644.
76. Moore N, Bosco-Levy P, Thurin N, et al. NSAIDs and COVID-19: a systematic review and meta-analysis. Drug Saf 2021; 44: 929–938.

77. See YP, Young BE, Ang LW, et al. Risk factors for development of acute kidney injury in COVID-19 patients: a retrospective observational cohort study. Nephron 2021; 145: 256–264.

78. Park J, Lee SH, You SC, et al. Non-steroidal anti-inflammatory agent use may not be associated with mortality of coronavirus disease 19. Sci Rep 2021; 11: 1–7.

79. Baghaki S, Yalcin CE, Baghaki HS, et al. COX2 inhibition in the treatment of COVID-19: review of literature to propose repositioning of celecoxib for randomized controlled studies. Int J Infect Dis 2020; 101: 29–32.

80. Cacciapuoti F and Cacciapuoti F. Could low doses acetylsalicylic acid prevent thrombotic complications in COVID-19 patients? Clin Appl Thromb Hemost 2021; 27: 10760296211014592.

81. Nudy M, Cooper J, Ghahramani M, et al. Aspirin for primary atherosclerotic cardiovascular disease prevention as baseline risk increases: a meta-regression analysis. Am J Med 2020; 133: 1056–1064.

82. Siegel AJ. Aspirin use for primary cardiovascular prevention during the COVID-19 pandemic. Am J Med 2021; 134: e299.

83. Kim I, Yoon S, Kim M, et al. Aspirin Is Related to Worse Clinical Outcomes of COVID-19. Medicina 2021; 57: 931.

84. Kow CS and Hasan SS. Use of antiplatelet drugs and the risk of mortality in patients with COVID-19: a meta-analysis. J Thromb Thrombolysis 2021; 52: 124–129.

85. Srivastava R and Kumar A. Use of aspirin in reduction of mortality of COVID-19 patients: a meta-analysis. Int J Clin Pract 2021; 75: e14515.

86. Sahai A, Bhandari R, Godwin M, et al. Effect of aspirin on short-term outcomes in hospitalized patients with COVID-19. Vasc Med 2021; 26: 626–632.

87. Salah MMG, Saleem M, Kheiri B, et al. Meta-analysis of the effect of aspirin on mortality in COVID-19. Am J Cardiol 2021; 142: 158–159.

88. Hemilä H and Chalker E. Vitamin C and zinc lozenges for COVID-19? J Am Pharm Assoc 2021; 61: e39.

89. Fowler AA, Syed AA, Knowlson S, et al. Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis. J Transl Med 2014; 12: 1–10.

90. Carr AC and Rowe S. The emerging role of Vitamin C in the prevention and treatment of COVID-19. Nutrients 2020; 12: 3286.

91. Lykkesfeldt J and Tveden-Nyborg P. The pharmacokinetics of Vitamin C. Nutrients 2019; 11: 2412.

92. Waheed S, Zahid RO, Khan ST, et al. Vitamin D (Cholecalciferol) with low dose Vitamin C as a safe and effective therapeutic modality in an adult with COVID-19 pneumonia. J Coll Physicians Surg Pak 2021; 31: S90–S92.

93. Hemilä H, Carr A and Chalker E. Vitamin C and zinc lozenges for COVID-19? J Am Pharm Assoc 2021; 61: e39.

94. Tomasa-Irriguible TM and Bielsa-Berrocal L. COVID-19: up to 82% critically ill patients had low Vitamin C values. Nutr J 2021; 20: 66.

95. Milani GP, Macchi M and Guz-Mark A. Vitamin C in the treatment of COVID-19. Nutrients 2021; 13: 1172.

96. Hemilä H, Carr A and Chalker E. Vitamin C may increase the recovery rate of outpatient cases of SARS-CoV-2 infection by 70%: reanalysis of the COVID A to Z randomized clinical trial. Front Immunol 2021; 12: 674681.

97. Thomas S, Patel D, Bittel B, et al. Effect of high-dose zinc and ascorbic acid supplementation vs usual care on symptom length and reduction among ambulatory patients with SARS-CoV-2 infection: the COVID A to Z randomized clinical trial. JAMA Netw Open 2021; 4: e210369.

98. Huang L, Wang L, Tan J, et al. High-dose Vitamin C intravenous infusion in the treatment of patients with COVID-19: a protocol for systematic review and meta-analysis. Medicine 2021; 100: e25876.

99. Toscano GADS, de Araújo II, de Souza TA, et al. Vitamin C and D supplementation and the severity of COVID-19: a protocol for systematic review and meta-analysis. Medicine 2021; 100: e26427.

100. Marik PE. Is intravenous Vitamin C contraindicated in patients with G6PD deficiency? Crit Care 2019; 23: 109.

101. Burela A, Hernández-Vásquez A, Comandé D, et al. Dióxido de Cloro y Derivados Del Cloro Para Prevenir o Tratar La COVID-19: Revisión
102. Tan HK, Wheeler WB and Wei CI. Reaction of chlorine dioxide with amino acids and peptides: kinetics and mutagenicity studies. *Mutat Res* 1987; 188: 259–266.

103. Ogata N. Inactivation of influenza virus haemagglutinin by chlorine dioxide: oxidation of the conserved Tryptophan 153 residue in the receptor-binding site. *J Gen Virol* 2012; 93(Pt. 12): 2558–2563.

104. Harcourt J, Tamin A, Lu X, *et al.* Severe acute respiratory syndrome coronavirus 2 from patient with coronavirus disease, United States. *Emerg Infect Dis* 2020; 26: 1266–1273.

105. Kály-Kullai K, Wittmann M, Noszticzius Z, *et al.* Can chlorine dioxide prevent the spreading of coronavirus or other viral infections? Medical hypotheses. *Physiology Int* 2020; 107: 1–11.

106. Burton MJ, Clarkson JE, Goulao B, *et al.* Antimicrobial mouthwashes (gargling) and nasal sprays administered to patients with suspected or confirmed COVID-19 infection to improve patient outcomes and to protect healthcare workers treating them. *Cochrane Database Syst Rev* 2020; 9: CD013627.

107. Organización Panamericana de la Salud La OPS No Recomienda Tomar Productos Que Contengan Dióxido de Cloro, Clorito de Sodio, Hipoclorito de Sodio o Derivados, 16 de Julio Del 2020. 2020.